logo
Fear contractor may quit if HNZ still ‘changing minds'

Fear contractor may quit if HNZ still ‘changing minds'

Pete Hodgson. PHOTO: PETER MCINTOSH
One of the former leaders of the new Dunedin hospital project is worried the protracted negotiations will convince the lead contractor to "walk away", resulting in the project's costs spiralling out of control.
It comes after the Otago Daily Times reported CPB Contractors' lawyer, Tom Horder, had publicly slammed the government's approach to contracting major infrastructure projects.
The Australian construction giant is set to build the new Dunedin hospital, but Mr Horder said New Zealand governments over the past decade had gone with the lump-sum model for contracts, which had been inappropriately applied to major projects, with "disastrous" results.
Former Labour health minister Pete Hodgson, who led the early stages of the project, said Mr Horder's remarks were "concerning, to say the least".
"If Health New Zealand Te Whatu Ora [HNZ] go back to the market, sooner or later CPB are going to say, we will not build this thing at a fixed price at $1.88 billion because we won't get subbies [subcontractors] to come and do their bit."
Mr Hodgson said there was always a risk of unknown problems with major infrastructure projects.
"It probably just goes with the territory that you walk into problems that will have to be resolved once they've been discovered — and you can't prediscover them."
He described HNZ's approach to contracting the new hospital as a "shambles" and a potential reputational risk.
"If CPB pull out, then I'm sure [Christchurch-based construction company] Southbase and others would look at it, but they would be adding money, and some of that money would be the risk of the client's behaviour.
"They cannot stop changing their minds."
This would lead to further delays and ballooning costs beyond the $1.88b set aside by the government, he said.
"HNZ have been deciding and undeciding themselves for years now and that means that the Crown, or the health system, will get a reputation across Australasia for being a bad client. That puts the price up."
The project was delayed for several months last year after the government deliberated over whether to build a new hospital on the former Cadbury's site or retrofit the existing hospital.
Financial commentator Bernard Hickey told the ODT he would not be surprised if CPB decided to walk away from the contract.
"It was a mistake [to stop work] because it alienated and shocked so many people who had geared up for significant infrastructure spending for many years; they had invested in people, invested in plant.
"When you're in the contracting game, you need certainty."
An HNZ spokesman said it was progressing commercial negotiations with CPB and was also finalising designs following decisions announced by the new Minister of Health, Simeon Brown, in January.
"While negotiations are continuing, Health NZ is progressing work to get pile capping and foundations work under way by the middle of this year."
Mr Horder has been contacted for comment.
Mr Brown met CPB on February 3.
"Contract negotiations for the completion of the new Dunedin hospital are being led by HNZ," Mr Brown said yesterday.
"What matters now is getting the best possible value for taxpayers — and delivering the hospital that the people of Otago and Southland have been waiting far too long for.
"New Zealanders elected this government because they wanted action, not excuses. ... This government is focused on delivery — and that's exactly what we are doing."
matthew.littlewood@odt.co.nz

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Despite Being Preventable And Curable Cervical Cancer Remains 4th Biggest Cancer In Women
Despite Being Preventable And Curable Cervical Cancer Remains 4th Biggest Cancer In Women

Scoop

time5 hours ago

  • Scoop

Despite Being Preventable And Curable Cervical Cancer Remains 4th Biggest Cancer In Women

Cervical cancer (cancer of the cervix) is preventable and curable, only if it is detected early and managed effectively. Yet it is the 4th most common cancer among women worldwide, with the disease occurring in 660,000 women and claiming the lives of 350,000 women in 2022 worldwide, as per the World Health Organization (WHO). China, India, and Indonesia had the highest number of cervical cancer cases in 2022. Moreover 42% of cervical cancer cases and 39% of deaths associated with it worldwide, took place in China and India- 23% cases and 16% deaths in China, and 19% cases and 23% deaths in India. India reported over 123,000 new cases of cervical cancer and around 77,000 deaths – highest number of deaths worldwide in 2022. Cervical cancer disproportionately affects younger women, and as a result, 20% of children who lose their mother to cancer do so due to cervical cancer, says WHO. As cervical cancer is the only cancer that can be eliminated, the WHO Director General had called upon the governments in 2018 to eliminate it. All governments globally committed to do so by 2030 (by endorsing the global strategy to eliminate cervical cancer by 2030 at the World Health Assembly 2020). But despite some progress, the world is way off the mark from the elimination goal in 2025. Where cervical cancer burden is greatest, access to lifesaving services is most broken Cervical cancer reflects the global inequities between the Global North and the Global South: The highest rates of cervical cancer incidence and mortality are in low- and middle-income countries. In fact, 94% of the cervical cancer deaths in 2022 took place in these countries where access to health services is appalling. This reflects major health inequities which are driven by lack of access to vaccination, cervical cancer screening and treatment services. Prophylactic vaccination against human papilloma virus (HPV) - which is one of the most common sexually transmitted infections and which causes cervical cancer - and screening, and treatment of pre-cancer lesions are very cost-effective strategies to prevent cervical cancer. WHO's call to deliver on #HealthForAll dates to the 1970s, but even now gaping health inequities and injustices plague the health systems – especially in the Global South. Vaccines against HPV have existed since almost 20 years now. No surprise for guessing that both Cervarix (made by Glaxo) and Gardasil (made by Merck) were made in the rich nations – and their rollout in the Global South has been far from ideal. In 2022, India-based Serum Institute in collaboration with the Department of Biotechnology of the government of India developed India's first indigenously produced HPV vaccine called Cervavac. So, now there is a vaccine developed in the Global South too. But its rollout is far from ideal as of now. It is still not a part of India's public health programme, for instance. Same inequities block access to HPV screening in the Global South "Almost all cervical cancers (~95%) are caused by persistent HPV infection. Women living with HIV are 6 times more likely to develop cervical cancer compared to the general population, and an estimated 5% of all cervical cancer cases are attributable to HIV,' said Dr Kuldeep Singh Sachdeva, former head of Indian government's national TB and HIV programmes. Dr Sachdeva was speaking at the National Dialogue and stakeholder meet organised by National Coalition of People living with HIV in India (NCPI Plus) bringing together over 100 community leaders from almost all states of India. Dr Sachdeva currently leads Molbio Diagnostics as President and Chief Medical Officer. He was speaking ahead of 10th Asia-Pacific AIDS & Co-Infections Conference (APACC 2025), Japan; 2nd Asia Pacific Conference on Point of Care Diagnostics for Infectious Diseases (POC 2025), Thailand; and 13th International AIDS Society Conference on HIV Science (IAS 2025), Rwanda. Cervical cancer screening efforts in most settings of the Global South have long been hampered by reliance on outdated methods like pap smears and visual inspection with acetic acid (VIA) test, both of which suffer from poor sensitivity, high subjectivity, and dependence on specialised infrastructure. Advanced molecular HPV tests developed by the Global North, while highly accurate than pap smear and VIA, remain inaccessible for most women living in peripheral, rural, and resource-limited settings, especially of the Global South. India's first point-of-care HPV test that can be deployed at point-of-need in the Global South In April 2025, India's first ever indigenously developed RT-PCR molecular test for HPV on Truenat (called HPV-HR Plus) got an independent multi-centric validation done by Government of India's Department of Biotechnology, Biotechnology Industry Research Assistance Council (BIRAC) and Grand Challenges India. Truenat HPV-HR Plus test is made by Molbio Diagnostics in India. This independent validation of Truenat HPV-HR Plus was conducted under the study 'Validating Indigenous Human Papilloma Virus (HPV) Tests for Cervical Cancer Screening in India.' The study involved leading Indian government's research institutes, including All India Institute of Medical Sciences (AIIMS) Delhi, ICMR National Institute for Cancer Prevention and Research (NICPR) Noida, and ICMR National Institute for Research in Reproductive and Child Health (NIRRCH) Mumbai, in collaboration with WHO's International Agency for Research on Cancer (IARC). There are over 200 genotypes of HPV but those that put the infected person at risk of developing cervical cancer are few. Truenat HPV-HR Plus molecular test enables detection for 8 HPV high-risk genotypes – which account for over 96% cervical cancer cases worldwide. These HPV high-risk genotypes include 16, 18, 31, 33, 35, 45, 52 and 58. Out of these, 16 and 18 high-risk genotypes dominate globally as 77% of invasive cervical cancer cases are associated with them. These high-risk genotypes can also cause cancer of the anus, penis, vagina, vulva, and oropharynx (throat). Raising cervical cancer awareness and health literacy among people with HIV As women living with HIV are 6 times more at risk of cervical cancer, communities and networks of people with HIV must come forward to find ways to integrate cervical cancer screening as well as for other cancers (such as breast cancer) programmatically and in people-centred manner, said Daxa Patel, co-founder of National Coalition of People living with HIV in India (NCPI Plus) and its former President. Agrees Pooja Mishra, Secretary of NCPI Plus that it is unacceptable when cervical cancer, which is preventable and curable - and the only cancer which can be eliminated - still kills 350,000 women worldwide. We also need to raise awareness, health and treatment literacy among the young people, said Mishra. That is why NCPI Plus took leadership in organising a national dialogue and stakeholder consultation on preventing cancers among people with HIV, especially women. Truenat HPV-HR Plus test is critical for closing the screening gap, particularly for asymptomatic women and women who are at higher risk for persistent HPV infection. By shifting HPV screening closer to the most-at-risk people and communities, this test ensures early detection, better triaging, and timely treatment - especially in historically underserved populations. Over 10,000 Truenat RT-PCR molecular test machines are already deployed globally in over 85 countries (mostly for TB), and mostly in the Global South nations in remote settings. Truenat is a battery operated (with solar power charging), laboratory independent, de-centralised and point-of-care test that provides highly accurate diagnosis for over 30 diseases (including TB, HPV, HCV, HBV, STIs, COVID-19, etc) within an hour – thus enabling same day test and treat, counselling and follow-up. Superiority of Truenat HPV-HR Plus test Older Pap smear test detects precancerous or cancerous cervical cancer cells whereas Truenat HPV-HR Plus test detects the presence of high-risk HPV DNA (8 genotypes). Pap smear is a cytological screening test and depends on the observing medical expert's skill and slide quality, whereas Truenat is a PCR-based nuclear acid amplification test with very high sensitivity and specificity. False negative reports are higher and false positive reports are also moderate when pap smear is used whereas both are low with Truenat HPV-HR Plus. The most recent validation of Truenat HPV-HR Plus showed 100% specificity and 100% sensitivity. Truenat HPV-HR is designed to work with cervical swab samples collected by a clinician (self-collection of samples is still under evaluation), and it gives highly accurate results in just 60 minutes. Whereas, a pap smear results may take 3-7 days as these are laboratory dependent. Easy to use and with high stability at room temperature, Truenat HPV-HR Plus requires minimal biosafety and is optimised for use at both the laboratory and near-patient settings. This test overcomes shortcomings of current diagnostic methods, including variable sensitivity and specificity, high costs, complex workflows, and dependence on advanced equipment, said Dr Sachdeva. Highlighting the importance of developing health technologies in the Global South, Rajesh S Gokhale, Secretary, Department of Biotechnology, Ministry of Science and Technology, Government of India said, 'Truenat HPV-HR Plus represents the kind of diagnostic innovation we need - dependable, scientifically rigorous, locally developed, and built to serve our public health system. It is a huge step forward in strengthening cervical cancer screening across India.' "HPV infection is common. However, persistence of HPV infection could be deadly. Studies show that nearly half of persistent HPV infections do not resolve by 24 months. These silent carriers drive the progression to high-grade pre-cancerous lesions and cancer. That's why extended HPV genotype detection is crucial," shared Dr Sachdeva. HPV also causes oropharyngeal cancers Oropharyngeal cancers related to HPV vary from 28% to 68% in the richer nations. Indian studies also show alarming numbers though, more research is needed for science-informed responses towards eliminating HPV related cancers in our population, said Dr Ishwar Gilada, President Emeritus of AIDS Society of India (ASI) and Governing Council member of International AIDS Society (IAS). 'While there is increasing evidence of HPV-associated oropharyngeal cancer in both men and women globally, there still remain gaps in gender-neutral HPV vaccination policies globally,' said Dr Sachdeva. Community leaders like Manoj Pardeshi, who is among the co-founders and inspiring lights of NCPI Plus, said that regardless of gender, all those eligible and at risk of HPV related cancers, must be vaccinated against HPV. Programme addressing cervical cancer elimination should expand to eliminate all HPV related cancers in people-centred ways, regardless of gender. HPV is transmitted through: - Sexual contact: Transmission mode is through vaginal, anal, or oral sex with an infected person. - Skin-to-skin contact: Transmitted through non-penetrative sexual activities involving skin-to-skin contact. The WHO Guidelines recommend HPV detection via molecular test after age of 30 (and every 5 years thereafter). Vaccination against HPV is highly recommended for younger people under the age of 15 or before the initiation of sexual activity. Do not leave equity behind 'Truenat HPV-HR Plus test is about equity in detection. By expanding beyond traditional targets, we reach the genotypes that matter more in our populations for cervical cancer elimination. This means earlier intervention, fewer missed cases, and better outcomes,' said Dr Sachdeva. Truenat HPV-HR Plus offers the best of both worlds - critical genotype coverage and real-world deploy-ability. What does it mean to eliminate cervical cancer by 2030? To eliminate cervical cancer, all countries must reach and maintain an incidence rate of below 4 per 100,000 women. Achieving that goal rests on three key pillars and their corresponding targets: vaccination: 90% of all eligible young people must be fully vaccinated with the HPV vaccine by the age of 15. screening: 70% of women should be screened using a high-performance test by the age of 35, and again by the age of 45; treatment: 90% of women with pre-cancer treated and 90% of women with invasive cancer managed. No other cancer but cervical cancer is fully preventable and curable if detected and managed early. Even one death from it is a death too many. Shobha Shukla – CNS (Citizen News Service) (Shobha Shukla is the award-winning founding Managing Editor and Executive Director of CNS (Citizen News Service) and is a feminist, health and development justice advocate. She is a former senior Physics faculty of prestigious Loreto Convent College and current Coordinator of Asia Pacific Regional Media Alliance for Health and Development (APCAT Media) and Chairperson of Global AMR Media Alliance (GAMA received AMR One Health Emerging Leaders and Outstanding Talents Award 2024). She also coordinates SHE & Rights initiative (Sexual health with equity & rights). Follow her on Twitter @shobha1shukla or read her writings here

Christchurch Hospital clinical director John O'Donnell retires after 42 years
Christchurch Hospital clinical director John O'Donnell retires after 42 years

RNZ News

time9 hours ago

  • RNZ News

Christchurch Hospital clinical director John O'Donnell retires after 42 years

Christchurch clinical director of immunology/immunopathology John O'Donnell in his lab. Photo: Supplied/Te Whatu Ora After 42 years working at Christchurch Hospital, John O'Donnell says it still feels like he just started yesterday. O'Donnell retired on Friday, 6 June, as clinical director of immunology/immunopathology. He started his time at Christchurch Hospital in 1977, as a medical student, moving up from Dunedin. After three years, he left for Waikato and was then based in a couple of other spots, including two years back in Christchurch, but by 1989, he was back as a consultant and he has remained ever since. O'Donnell has seen many changes in his time there, with the most notable being the complete change in the hospital buildings and the huge advances in computing technology. "When I started, there was no internet and there have been huge advances in computing technology," he said. "Email didn't exist, so communication is much more rapid, with cell phones and things like that. When we were on call, people used to carry around these bricks of a phone. I inherited one of those bricks to carry around." He said in laboratories, the automating of testing had also been a big change, although less so in his specialty area of immunology, where some testing still needed to be done manually. "You still get the scientist standing at a bench and pipetting things." He said there were also big changes in the understanding of the immune system. "Increasingly, it is recognised that many diseases we deal with are an aberration of the immune response. Certain diseases, like encephalitis or certain muscle diseases, it's the immune system attacking those organs to produce some quite bizarre changes in those organs, which we never thought of as being part of us, in terms of our immune system, going haywire. "We often saw them as perhaps a virus or some other thing, but often, it turns out it is the immune system attacking things." In Christchurch, he said there was an interest in muscle diseases and particularly those triggered by statin use. "Its a very rare complication, but it is one of the interests we have locally, testing for that sort of disorder called auto-immune myositis - an auto immune muscle inflammation. We have done some work and publications in that area." He still found the area fascinating and was amazed how quickly his time in the job had gone by. "I could have started yesterday." As he departed after more than 40 years, O'Donnell said the health system was going through its third major shake-up. "Health is always under strain," he said. "It's inevitable it will change. I don't think it's particularly helpful people yelling and posturing. Everybody knows there is a strain and we have to work together to come up with a system that works, without extracting things from other people all the time. "We have to work together and realise what the limitations are, and be realistic about what we can deliver, without crashing the system entirely." Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.

Health needs to be put to ministers
Health needs to be put to ministers

Otago Daily Times

time12 hours ago

  • Otago Daily Times

Health needs to be put to ministers

Wānaka's most vocal health advocacy group will be demanding more publicly funded services for the region in upcoming meetings with health ministers. Health Action Wānaka have secured a private meeting with the Minister of Health Simeon Brown on July 1 in Auckland, in addition to a meeting with Associate Health Minister Matt Doocey on the same day, during his visit to Wānaka for the Rural Health Roadshow. The group published a health report two months ago exposing urgent unmet health needs in the region and criticising the lack of strategic health planning to meet the Upper Clutha's rapid population growth. Before publishing the report, Health Action Wānaka wrote to Mr Brown sharing their findings and requesting a meeting which they were offered a day after the report went public. As part of the report, they worked with healthcare providers and interviewed locals who have faced inequity when trying to access services. The report exposed gaps across a range of services including mental health, maternity care and aged care, while also highlighting key barriers, such as travel costs, for locals trying to access healthcare in the region. Four members of the group's steering committee are set to travel to Auckland next month for a meeting with Mr Brown, while the remaining member and two representatives from youth mental health NGO, ADL will meet Mr Doocey. Health Action Wānaka spokesperson Monique Mayze said in a statement that they wanted to leave both meetings feeling confident the ministers were considering their recommendations. Part of the group's proposal are three "quick wins" which will include the introduction of telehealth psychiatric consultations, publicly funded blood collection within the next two years and funded radiology services. Ms Mayze said that with the strong evidence they have collected, the ministers will be held directly accountable to the local community for what they choose to do with the information. "Sometimes you have to be the squeaky wheel to get stuff done," she said. "And that's what we will continue to be until our community gets access to the publicly funded health services it needs". The group announced both meetings on their social media and called for community involvement as they plan the specific questions they want to ask during the meetings. They are also urging the community to attend the public questions and answers event with Mr Doocey as a way of showing solidarity in the fight for a more equitable healthcare system. "We need hundreds of locals to turn up," Ms Mayze said. " ... to send a message to Minister Doocey and Minister Brown that something has to be done about the health services inequity in our community." The group's meeting with Mr Doocey will take place before the public event and will be attended by one member of Health Action Wānaka and two representatives from ADL. Ms Mayze said the representatives from ADL will be able to give Mr Doocey insights into the reality of mental health services in the region. This will also help make a strong case for the group's proposal to introduce psychiatric telehealth services for NGOs like ADL. The public event will be held on July 1 at the Lake Wanaka Centre, from 12pm to 1.30pm, as part of the Rural Health Roadshow.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store